01 15Nexium
02 1Vimovo
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 717
2019 Revenue in Millions : 729
Growth (%) : -2
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 1,492
2019 Revenue in Millions : 1,483
Growth (%) : 1
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 478
2020 Revenue in Millions : 713
Growth (%) : -28
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 1,326
2020 Revenue in Millions : 1,492
Growth (%) : -11
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 1,285
2021 Revenue in Millions : 1,326
Growth (%) : -3
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 945
2022 Revenue in Millions : 1,285
Growth (%) : -26
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2015 Revenue in Millions : 3,655
2014 Revenue in Millions : 2,496
Growth (%) : -32%
Naproxen + Esomeprazole Magnesium
Main Therapeutic Indication : Bone Health
Currency : USD
2015 Revenue in Millions : 96
2014 Revenue in Millions : 0
Growth (%) : -100%
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 1,952
2016 Revenue in Millions : 2,032
Growth (%) : -4
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2014 Revenue in Millions : -5.60%
2013 Revenue in Millions :
Growth (%) :
LOOKING FOR A SUPPLIER?